Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)

por Zinman, Bernard, Inzucchi, Silvio E, Lachin, John M, Wanner, Christoph, Ferrari, Roberto, Fitchett, David, Bluhmki, Erich, Hantel, Stefan, Kempthorne-Rawson, Joan, Newman, Jennifer, Johansen, Odd Erik, Woerle, Hans-Juergen, Broedl, Uli C
Publicado 2014